## WHAT IS CLAIMED IS:

1. A compound of the Formula:

$$R_1$$
 $R_3$ 
 $R_8$ 
 $R_8$ 
 $R_8$ 
 $R_8$ 

or a pharmaceutically acceptable salt thereof, wherein:

5 G is oxygen or NH;

15

20

R<sub>x</sub> is straight or branched chain C<sub>1-8</sub>alkyl;

R<sub>1</sub> and R<sub>3</sub> are independently selected from hydrogen, C<sub>1-4</sub> alkyl, halogen, C<sub>1-2</sub> haloalkyl, C<sub>1-2</sub>haloalkoxy, mono- and di-C<sub>1-4</sub>alkylamino, C<sub>1-4</sub>alkoxy, and C<sub>1-4</sub> alkylthio;

R<sub>5</sub> is halogen, C<sub>1-4</sub>alkyl, or C<sub>1-4</sub>alkoxy;

10 R<sub>6</sub> is hydrogen, halogen, C<sub>1-2</sub>alkyl, or C<sub>1-2</sub>alkoxy;

R<sub>7</sub> is halogen, halogen, cyano, C<sub>1-4</sub>alkyl, C<sub>1-4</sub>alkoxy, C<sub>1-2</sub> haloalkyl, C<sub>1-2</sub>haloalkoxy, monoand di-C<sub>1-4</sub>alkylamino, mono- and di-(C<sub>1-2</sub>alkyl)aminoC<sub>1-4</sub>alkyl, C<sub>1-2</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>1-2</sub>alkoxycarbonyl, C<sub>1-2</sub>alkylcarboxaminde, -C(=O)NH<sub>2</sub>, hydroxyC<sub>1-2</sub>alkyl, trifluoromethylsulfonyl, 2,2,2-trifluoroethanol, or a 4-7 membered heterocycloalkyl group containing 1 or 2 atoms independently chosen from N, O, and S;

R<sub>8</sub> is hydrogen, halogen, C<sub>1-2</sub>alkyl, or C<sub>1-2</sub>alkoxy; and J is N or CR<sub>9</sub> where R<sub>9</sub> is hydrogen, halogen or C<sub>1-2</sub>alkyl.

- 2. A compound or salt according to Claim 1 wherein  $R_1$  and  $R_3$  are not hydrogen.
- 3. A compound or salt according to Claim 1 wherein J is nitrogen and  $R_6$  is hydrogen.
- 4. A compound or salt according to Claim 1 wherein J is CH and R<sub>6</sub> is hydrogen.
- 5. A compound or salt according to Claim 1wherein G is NH and R<sub>X</sub> is 1-ethyl propyl.
  - 6. A compound or salt according to Claim 5 wherein  $R_1$  is cyano, methoxy, or methylthio and  $R_3$  is methyl or ethyl.

- 7. A compound or salt according to Claim 1 wherein G is oxygen and  $R_X$  is 1-ethylpropyl, 1-isopropyl-2-methypropyl, 1-propylbutyl, or 1-ethylbutyl.
- 8. A compound or salt according to Claim 7 wherein R<sub>3</sub> is halogen, C<sub>1-2</sub>alkyl, or methylamino.
  - 9. A compound or salt according to Claim 7 wherein  $R_1$  is halogen, methyl, methoxy, ethyl, ethoxy, or  $C_{1-2}$ alkylamino.
    - 10. A compound or salt according to Claim 7 wherein R<sub>1</sub> is methylamino.
  - 11. A compound according to Claim 1 which is selected from 5-ethyl-6-(1-ethylpropoxy)-3-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
    - 5-bromo-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
    - 3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;
- 20 2-(4-tert-butyl-2-methoxyphenyl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine;

10

15

- 2-(4-tert-butyl-2-methoxyphenyl)-3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazine;
- 2,5-diethyl-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)pyrazine;
- 2,5-diethyl-3-(4-isopropyl-2-methoxyphenyl)-6-(1-isopropyl-2-methylpropoxy)pyrazine;
- 2-(2,6-dimethoxypyridin-3-yl)-3,6-diethyl-5-(1-ethylpropoxy)pyrazine;
- 25 2-(2,6-dimethoxypyridin-3-yl)-3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazine;
  - 2,5-diethyl-3-(4-ethyl-2-methoxyphenyl)-6-(1-ethylpropoxy)pyrazine;
  - 2-[2-chloro-4-(difluoromethoxy)phenyl]-3,6-diethyl-5-(1-propylbutoxy)pyrazine;
  - 2,5-diethyl-3-(1-ethylbutoxy)-6-(4-isopropyl-2-methoxyphenyl)pyrazine;
  - 2,5-diethyl-3-(1-ethylpropoxy)-6-(2-fluoro-4,6-dimethoxyphenyl)pyrazine; and
- 30 2,5-diethyl-3-(2-fluoro-4,6-dimethoxyphenyl)-6-(1-isopropyl-2-methylpropoxy)pyrazine;
  - 2,5-diethyl-3-(4-isopropyl-2-methoxyphenyl)-6-(1-propylbutoxy)pyrazine;
  - 5-(1-ethylpropoxy)-2-[2-methoxy-4-(trifluoromethoxy)phenyl]-3-methylpyrazine;
  - 2-chloro-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyrazine;

- 2-(1-ethylpropoxy)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazine; 6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
- 5-[3,6-diethyl-5-(1-isopropyl-2-methylpropoxy)pyrazin-2-yl]-6-methoxy-N,N-
- 5 dimethylpyridin-2-amine;
  - 5-bromo-6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
  - 2-chloro-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-5-methylpyrazine;
  - 3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
- 5-(1-ethylpropoxy)-2-[2-methoxy-4-(trifluoromethyl)phenyl]-3-methylpyrazine; 5-bromo-3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
  - 2-chloro-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-5-methylpyrazine;
  - 3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;
- 15 3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,5-dimethylpyrazin-2-amine; and
  - 5-bromo-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-
- 20 amine;
  - 5-bromo-6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine:
  - 6-[4-(difluoromethoxy)-2-methoxyphenyl]-3-(1-ethylbutoxy)-N,5-dimethylpyrazin-2-amine;
  - 5-bromo-6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-
- amine;
  - 6-(4-ethoxy-2-methoxy-5-methylphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
  - 5-bromo-6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
  - 5-bromo-6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
  - 5-bromo-3-ethoxy-6-(4-ethoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
- 30 6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N,5-dimethylpyrazin-2-amine;
  - 6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
  - 6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine;
  - 5-bromo-6-(4-ethoxy-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;

- 6-(4-ethoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
- 5-bromo-3-(1-ethylbutoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
- 6-(4-ethoxy-2-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
- 5-bromo-6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-
- 5 amine;
  - 6-(5-bromo-4-ethoxy-2-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine;
  - 6-(4-ethoxy-2-methoxy-5-methylphenyl)-3-(1-ethylbutoxy)-N,5-dimethylpyrazin-2-amine;
  - 5-bromo-3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methylpyrazin-2-
  - amine;
- 5-bromo-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 3-(1-ethylbutoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,5-dimethylpyrazin-2-amine;
  - 6-[2-methoxy-4-(trifluoromethyl)phenyl]-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 5-bromo-3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
- 15 3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
  - 3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N,5-dimethylpyrazin-2-amine;
  - 5-ethyl-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N-methylpyrazin-2-
  - amine;
  - 3-(1-ethylbutoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
- 20 6-(2-ethyl-4-methoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
  - 6-(2,4-dimethoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
  - 5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 6-[2-chloro-4-(trifluoromethyl)phenyl]-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-
- 25 carbonitrile;
  - 6-(2.6-dimethoxypyridin-3-yl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-carbonitrile;
  - 3-[(1-ethylpropyl)amino]-6-mesityl-5-methylpyrazine-2-carbonitrile;
  - 6-(4-chloro-2,6-dimethoxyphenyl)-3-[(1-ethylpropyl)amino]-5-methylpyrazine-2-
  - carbonitrile;
- 30 3-[(1-ethylpropyl)amino]-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-5-methylpyrazine-2-carbonitrile;
  - 5-[2-chloro-4-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;

- 5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
- 5-[6-(dimethylamino)-2-ethylpyridin-3-yl]-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
- 5-bromo-6-(2-chloro-4-isopropoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine; 5-bromo-6-(2-chloro-4-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine; 6-(2-chloro-4-methoxyphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine; 6-(2-chloro-4-isopropoxyphenyl)-3-(1-ethylpropoxy)-N,5-dimethylpyrazin-2-amine; N-(1-ethylpropyl)-5-mesityl-3-methoxy-6-methylpyrazin-2-amine;
- 5-[6-(dimethylamino)-2,4-dimethylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
   3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methylphenyl)-N,5-dimethylpyrazin-2-amine;
   5-bromo-3-(1-ethylpropoxy)-6-[2-methoxy-4-(trifluoromethyl)phenyl]-N-methylpyrazin-2-amine;
- N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxypyrazin-2-amine; 5-bromo-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)-N-methylpyrazin-2-amine;
  - 5-bromo-6-(2-chloro-4-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 6-(2-chloro-4-methoxyphenyl)-5-ethyl-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
- 5-bromo-6-(2-chloro-4-methoxyphenyl)-3-(1-ethylbutoxy)-N-methylpyrazin-2-amine; 6-(2-chloro-4-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 2,5-diethyl-3-(1-ethylpropoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)pyrazine;
  - 3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N,5-dimethylpyrazin-2-amine;
- 3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
  - 5-bromo-3-{[(1S)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
  - $3-\{[(1R)-1-ethylbutyl]oxy\}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N, 5-dimethylpyrazin-1-ethylbutyl]oxy\}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N, 5-dimethylpyrazin-1-ethylbutyl]oxy\}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N, 5-dimethylpyrazin-1-ethylbutyl]oxy\}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N, 5-dimethylpyrazin-1-ethylbutyl]oxy\}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N, 5-dimethylpyrazin-1-ethylpyrazin-$
- 30 2-amine;
  - 3-{[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;

```
5-bromo-3-{[(1R)-1-ethylbutyl]oxy}-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N-methylpyrazin-2-amine;
```

- 5-(2,4-dimethoxypyrimidin-5-yl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
- 5-(2,4-dimethoxypyrimidin-5-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
- 5 N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-6-methyl-3-(methylthio)pyrazin-2-amine;
  - 6-(2-chloro-4-methoxyphenyl)-3-(1-ethylbutoxy)-N,5-dimethylpyrazin-2-amine;
  - 3-(1-ethylbutoxy)-6-(4-methoxy-2-methylphenyl)-N,5-dimethylpyrazin-2-amine;
  - 5-bromo-6-(2-chloro-4-ethoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
- 5-bromo-6-(2-chloro-4-ethoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 2,5-diethyl-3-(1-ethylbutoxy)-6-(6-isopropyl-2-methoxypyridin-3-yl)pyrazine;
  - 5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 5-[6-(dimethylamino)-2-methoxypyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-
- 15 methylpyrazin-2-amine;
  - N-(1-ethylpropyl)-3,6-dimethoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]pyrazin-2-amine;
  - methyl 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxybenzoate;
- 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxy-N-methylbenzamide;
  - 5-bromo-6-(4-isopropoxy-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 3-(1-ethylpropoxy)-6-(4-isopropoxy-2-methoxyphenyl)-N-methylpyrazin-2-amine;
  - 6-ethyl-N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-3-methoxypyrazin-2-amine;
- N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
  - 5-{4-[(dimethylamino)methyl]-2,6-dimethoxyphenyl}-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 1-(4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxyphenyl)-
- 30 2,2,2-trifluoroethanol;
  - 5-(2,6-dimethoxypyridin-3-yl)-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 5-(2,6-dimethoxypyridin-3-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
  - 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxybenzamide;

- 2-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-5-(trifluoromethoxy)phenol; 6-(4-isopropoxy-2-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine; 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxy-N,N-dimethylbenzamide;
- 5 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-N,3,5-trimethoxy-N-methylbenzamide;
  - 5-bromo-6-(5-bromo-4-isopropoxy-2-methoxyphenyl)-3-(1-ethylpropoxy)-N-methylpyrazin-2-amine;
  - 2,5-diethyl-3-(1-ethylpropoxy)-6-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]pyrazine;
- N-(1-ethylpropyl)-5-(6-isopropyl-4-methoxypyridin-3-yl)-3-methoxy-6-methylpyrazin-2-amine;
  - 5-(2-chloro-6-isopropylpyridin-3-yl)-6-ethyl-N-(1-ethylpropyl)-3-methoxypyrazin-2-amine;
  - 5-bromo-3-(1-ethylbutoxy)-6-(4-isopropyl-2-methoxyphenyl)-N-methylpyrazin-2-amine;
  - 5-bromo-3-(1-ethylpropoxy)-6-(4-isopropyl-2-methoxyphenyl)-N-methylpyrazin-2-amine;
- 5-bromo-6-(4-isopropyl-2-methoxyphenyl)-N-methyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 3-ethoxy-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
  - 6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethyl-3-(1-propylbutoxy)pyrazin-2-amine;
  - 3-(1-ethylbutoxy)-6-(4-isopropyl-2-methoxyphenyl)-N,5-dimethylpyrazin-2-amine;
  - N<sup>2</sup>-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazine-2,3-
- 20 diamine;
  - N<sup>2</sup>-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-6-methylpyrazine-2,3-diamine; 5-bromo-N<sup>3</sup>-(1-ethylpropyl)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N<sup>2</sup>-methylpyrazine-2,3-diamine;
  - 5-(4-chloro-2,6-dimethoxyphenyl)-N<sup>2</sup>-(1-ethylpropyl)-6-methylpyrazine-2,3-diamine;
- N<sup>2</sup>-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-N<sup>3</sup>,N<sup>3</sup>,-6-trimethylpyrazine-2.3-diamine:
  - N<sup>2</sup>-(1-ethylpropyl)-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methylpyrazine-2,3-diamine;
  - $5-ethyl-N^3-(1-ethylpropyl)-6-[2-methoxy-4-(trifluoromethoxy)phenyl]-N^2-methylpyrazine-partial phenyllogram and the statement of the properties of the pr$
- 30 2,3-diamine;
  - N-(1-ethylpropyl)-5-(4-isopropyl-2,6-dimethoxyphenyl)-3-methoxy-6-methylpyrazin-2-amine;

- N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methylpyrazin-2-amine;
- 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]pyrazin-2-amine;
- 5 N-(1-ethylpropyl)-5-[4-(1-fluoro-1-methylethyl)-2,6-dimethoxyphenyl]-3-methoxy-6-methylpyrazin-2-amine;
  - D6-N-(1-ethylpropyl)-3-methoxy-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methylpyrazin-2-amine;
  - N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxy-6-methylpyrazin-2-
- 10 amine;
  - 6-ethyl-N-(1-ethylpropyl)-5-(6-isopropyl-2-methoxypyridin-3-yl)-3-methoxypyrazin-2-amine;
  - 6-ethyl-N-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-3-methoxypyrazin-2-amine;
  - N-(1-ethylpropyl)-5-(4-isopropyl-2-methoxyphenyl)-3-methoxy-6-methylpyrazin-2-amine;
- N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)-6-methylpyrazin-2-amine;
  - 5-[2,6-dimethoxy-4-(1,2,2,2-tetrafluoroethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 6-ethyl-N-(1-ethylpropyl)-3-methoxy-5-(2-methoxy-6-pyrrolidin-1-ylpyridin-3-yl)pyrazin-2-
- 20 amine;
  - (4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxyphenyl)methanol;
  - 5-[6-(dimethylamino)-2-methylpyridin-3-yl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
- 5-[2,6-dimethoxy-4-(1-methoxyethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 5-[4-(1-ethoxyethyl)-2,6-dimethoxyphenyl]-N-(1-ethylpropyl)-3-methoxy-6-methylpyrazin-2-amine;
  - 5-[2,6-dimethoxy-4-(methoxymethyl)phenyl]-N-(1-ethylpropyl)-3-methoxy-6-
- 30 methylpyrazin-2-amine;
  - 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3-methoxyphenyl trifluoromethanesulfonate;
  - 4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3-methoxybenzonitrile;

4-{5-[(1-ethylpropyl)amino]-6-methoxy-3-methylpyrazin-2-yl}-3,5-dimethoxybenzaldehyde O-methyloxime;

N-(1-ethylpropyl)-5-[2-methoxy-6-(trifluoromethyl)pyridin-3-yl]-6-methyl-3-(methylthio)pyrazin-2-amine;

- 5 5-(4-chloro-2,6-dimethoxyphenyl)-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
  - N-(1-ethylpropyl)-5-[2-methoxy-4-(trifluoromethoxy)phenyl]-6-methyl-3-(methylthio)pyrazin-2-amine;

15

20

- 5-(2,4-dimethoxyphenyl)-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine;
- 5-(2,6-dimethoxypyridin-3-yl)-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine; N-(1-ethylpropyl)-5-(4-fluoro-2-methoxyphenyl)-6-methyl-3-(methylthio)pyrazin-2-amine; 5-[2-chloro-4-(trifluoromethyl)phenyl]-N-(1-ethylpropyl)-6-methyl-3-(methylthio)pyrazin-2-amine; and
  - N-(1-ethylpropyl)-5-mesityl-6-methyl-3-(methylthio)pyrazin-2-amine, or a pharmaceutically acceptable salt thereof.
    - 12. A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K<sub>i</sub> value for CRF receptors of less than or equal to 1 micromolar.
    - 13. A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K<sub>i</sub> value for CRF receptors of less than or equal to 100 nanomolar.
- 14. A compound or salt according to Claims 1 wherein, in a standard in vitro CRF receptor binding assay, the compound exhibits a K<sub>i</sub> value for CRF receptors of less than or equal to 10 nanomolar.
- 15. A method for treating anxiety, depression, or stress comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.

- 16. A method for treating irritable bowel syndrome or Crohn's disease, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.
- 17. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of Claim 1.

5

10

15

20

25

30

- 18. A pharmaceutical composition according to Claim 17, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup or a transdermal patch.
- 19. A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising indicia comprising at least one of:
  instructions for using the composition to treat a patient suffering from anxiety, or instructions for using the composition to treat a patient suffering from stress, or

instructions for using the composition to treat a patient suffering from depression.

- 20. A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising at least one of: instructions for using the composition to treat a patient suffering from irritable bowel syndrome or instructions for using the composition to treat a patient suffering from Crohn's disease.
- 21. A method for demonstrating the presence or absence of CRF 1 receptors in a biological sample, said method comprising:
- a) contacting the biological sample with a labeled compound according to Claim 1 under conditions that permit binding of the labeled compound to a CRF1 receptor;
  - b) separating unbound labeled compound from bound labeled compound; and
- c) detecting the bound labeled compound in the biological sample, and therefrom determining the presence or absence of CRF1 receptors in the sample.
- 22. The method of Claim 21 wherein the labeled compound is detected using autoradiography.

23. A method of inhibiting the binding of CRF to a CRF1 Receptor, which method comprises:

contacting a solution comprising CRF and a compound or salt of Claim 1 with a cell expressing the CRF receptor, wherein the compound or salt is present in the solution at a concentration sufficient to inhibit *in vitro* CRF binding to IMR32 cells.

- 24. The method of Claim 23 wherein the cell expressing the CRF receptor is a neuronal cell that is contacted in vivo in an animal, and wherein the solution is a body fluid of said animal.
  - 25. The method of Claim 23 wherein the animal is a human patient.

5

10